Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

Danish investment firm Novo Holdings, which has invested in Manipal Hospitals and Qure.ai Technologies in India, has ...

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for a Stocks and Shares ISA.

Sinclair joins VCCP from Grey Health and Wellness, where she served as president for just over four years. Creative agency ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.